TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07905560: A First-In-Human, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Limited Duration Treatment, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Sponsor: Superluminal Medicines, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 138 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07905560 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07905560 Rescue Dossier →